ATE516024T1 - Behandlung von krankheiten im zusammenhang mit der anwendung von antibiotika - Google Patents

Behandlung von krankheiten im zusammenhang mit der anwendung von antibiotika

Info

Publication number: ATE516024T1
Authority: AT; Austria
Prior art keywords: antibiotics; treatment; compound; diseases related; resistant
Prior art date: 2004-05-14

Application number

AT05748007T

Other languages

English (en)

Inventor

Youe-Kong Shue

Farah Babakhani

Franklin Okumu

Pamela Sears

Starr Miller-Shangle

Robert Walsh

Original Assignee

Optimer Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-14

Filing date

2005-05-13

Publication date

2011-07-15

2005-05-13 Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE516024T1 publication Critical patent/ATE516024T1/de

Links

201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
239000003242 anti bacterial agent Substances 0.000 title 1
229940088710 antibiotic agent Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
241000193163 Clostridioides difficile Species 0.000 abstract 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 abstract 1
241000191967 Staphylococcus aureus Species 0.000 abstract 1
108010059993 Vancomycin Proteins 0.000 abstract 1
229960003085 meticillin Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
229960003165 vancomycin Drugs 0.000 abstract 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Virology (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)

AT05748007T 2004-05-14 2005-05-13 Behandlung von krankheiten im zusammenhang mit der anwendung von antibiotika ATE516024T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57069704P	2004-05-14	2004-05-14
PCT/US2005/016750 WO2005112990A2 (en)	2004-05-14	2005-05-13	Treatment of diseases associated with the use of antibiotics

Publications (1)

Publication Number	Publication Date
ATE516024T1 true ATE516024T1 (de)	2011-07-15

Family

ID=35428857

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05748007T ATE516024T1 (de)	2004-05-14	2005-05-13	Behandlung von krankheiten im zusammenhang mit der anwendung von antibiotika

Country Status (17)

Country	Link
US (2)	US20070173462A1 (de)
EP (4)	EP2305244B1 (de)
JP (2)	JP5734545B2 (de)
AT (1)	ATE516024T1 (de)
BR (1)	BRPI0511119A (de)
CA (2)	CA2776682A1 (de)
CY (2)	CY1117501T1 (de)
DK (3)	DK2305244T3 (de)
ES (4)	ES2395404T3 (de)
HU (3)	HUE027757T2 (de)
LT (1)	LT2305245T (de)
MX (2)	MX344601B (de)
PL (3)	PL2070530T3 (de)
PT (2)	PT2305244T (de)
SI (2)	SI2305245T1 (de)
TR (1)	TR201902533T4 (de)
WO (1)	WO2005112990A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006085838A1 (en) *	2005-01-31	2006-08-17	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US7906489B2 (en) *	2004-05-14	2011-03-15	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US8586551B2 (en)	2005-01-31	2013-11-19	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US7378508B2 (en)	2007-01-22	2008-05-27	Optimer Pharmaceuticals, Inc.	Polymorphic crystalline forms of tiacumicin B
CA2626698C (en) *	2005-10-21	2015-12-01	Optimer Pharmaceuticals, Inc.	Method of treating clostridium difficile-associated diarrhea
TWI523654B (zh) *	2007-11-27	2016-03-01	默沙東藥廠	抗生素巨環化合物以及其製造及使用之方法
US20110008303A1 (en) *	2008-03-17	2011-01-13	Cedars-Sinai Medical Center	Methods for treatment and prevention of mrsa/mssa
WO2011044208A1 (en) *	2009-10-06	2011-04-14	Scott Dorfner	Antibiotic formulations providing reduced gastrointentestinal side effects
AU2010320558A1 (en) *	2009-11-17	2012-07-12	Piramal Enterprises Limited	Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
MX348611B (es) *	2009-12-31	2017-06-21	Milton Trachtman Ira	Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
BR112012029259A8 (pt) *	2010-05-18	2021-03-23	Optimer Pharmaceuticals Inc	tratamento de infecção por clostridium difficile em pacientes sob terapia de antibióticos
JO3464B1 (ar)	2013-01-15	2020-07-05	Astellas Pharma Europe Ltd	التركيبات الخاصة بمركبات التياكوميسين
WO2015169451A1 (en)	2014-05-09	2015-11-12	Astellas Pharma Europe Ltd	Treatment regimen tiacumicin compound
MX2020005875A (es)	2017-12-05	2020-10-08	Bioplx Inc	Métodos y composiciones para prevenir la infección microbiana.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3279995A (en)	1963-05-31	1966-10-18	Allen F Reid	Shaped pellets
GB1458512A (en) *	1973-11-22	1976-12-15	Lepetit Spa	Antibiotic substance
US4111202A (en)	1976-11-22	1978-09-05	Alza Corporation	Osmotic system for the controlled and delivery of agent over time
US4918174A (en)	1986-09-26	1990-04-17	Abbott Laboratories	Tiacumicin compounds
US4786503A (en)	1987-04-06	1988-11-22	Alza Corporation	Dosage form comprising parallel lamine
US5443841A (en)	1992-06-15	1995-08-22	Emisphere Technologies, Inc.	Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en)	1992-04-24	2001-05-22	Brown University Research Foundation	Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) *	1995-05-09	1996-12-10	Abbott Laboratories	Dialkyltiacumicin compounds
US6143211A (en)	1995-07-21	2000-11-07	Brown University Foundation	Process for preparing microparticles through phase inversion phenomena
US5767096A (en) *	1996-07-12	1998-06-16	Abbott Laboratories	Bromotiacumicin compounds
IN186245B (de)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
ES2327830T3 (es) *	2002-03-29	2009-11-04	Schering Corporation	Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US20070105791A1 (en) *	2002-07-29	2007-05-10	Optimer Pharmaceuticals, Inc.	Method of treating clostridium difficile-associated diarrhea
US7507564B2 (en) *	2002-07-29	2009-03-24	Optimer Pharmaceuticals, Inc.	Tiacumicin production
US7906489B2 (en) *	2004-05-14	2011-03-15	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
US7378508B2 (en) *	2007-01-22	2008-05-27	Optimer Pharmaceuticals, Inc.	Polymorphic crystalline forms of tiacumicin B
US8586551B2 (en) *	2005-01-31	2013-11-19	Optimer Pharmaceuticals, Inc.	18-membered macrocycles and analogs thereof
ZA200905337B (en) *	2007-01-22	2010-10-27	Optimer Pharmaceuticals Inc	Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) *	2007-11-27	2016-03-01	默沙東藥廠	抗生素巨環化合物以及其製造及使用之方法

2005
- 2005-05-13 ES ES05748007T patent/ES2395404T3/es not_active Expired - Lifetime
- 2005-05-13 PL PL09156339T patent/PL2070530T3/pl unknown
- 2005-05-13 SI SI200532245T patent/SI2305245T1/sl unknown
- 2005-05-13 HU HUE09156339A patent/HUE027757T2/en unknown
- 2005-05-13 US US11/596,340 patent/US20070173462A1/en not_active Abandoned
- 2005-05-13 BR BRPI0511119-6A patent/BRPI0511119A/pt not_active IP Right Cessation
- 2005-05-13 DK DK10075449.8T patent/DK2305244T3/en active
- 2005-05-13 CA CA2776682A patent/CA2776682A1/en not_active Withdrawn
- 2005-05-13 TR TR2019/02533T patent/TR201902533T4/tr unknown
- 2005-05-13 HU HUE10075450A patent/HUE043945T2/hu unknown
- 2005-05-13 ES ES10075450T patent/ES2713954T3/es not_active Expired - Lifetime
- 2005-05-13 PL PL10075449T patent/PL2305244T3/pl unknown
- 2005-05-13 ES ES10075449.8T patent/ES2608046T3/es not_active Expired - Lifetime
- 2005-05-13 HU HUE10075449A patent/HUE031581T2/en unknown
- 2005-05-13 DK DK09156339.5T patent/DK2070530T3/da active
- 2005-05-13 EP EP10075449.8A patent/EP2305244B1/de not_active Expired - Lifetime
- 2005-05-13 WO PCT/US2005/016750 patent/WO2005112990A2/en not_active Ceased
- 2005-05-13 EP EP05748007A patent/EP1765312B1/de not_active Expired - Lifetime
- 2005-05-13 MX MX2014003990A patent/MX344601B/es unknown
- 2005-05-13 MX MXPA06013245A patent/MXPA06013245A/es active IP Right Grant
- 2005-05-13 AT AT05748007T patent/ATE516024T1/de not_active IP Right Cessation
- 2005-05-13 DK DK10075450.6T patent/DK2305245T3/en active
- 2005-05-13 PT PT100754498T patent/PT2305244T/pt unknown
- 2005-05-13 ES ES09156339.5T patent/ES2565609T3/es not_active Expired - Lifetime
- 2005-05-13 JP JP2007513392A patent/JP5734545B2/ja not_active Expired - Lifetime
- 2005-05-13 EP EP10075450.6A patent/EP2305245B1/de not_active Expired - Lifetime
- 2005-05-13 LT LTEP10075450.6T patent/LT2305245T/lt unknown
- 2005-05-13 PT PT10075450T patent/PT2305245T/pt unknown
- 2005-05-13 EP EP09156339.5A patent/EP2070530B1/de not_active Expired - Lifetime
- 2005-05-13 CA CA2566687A patent/CA2566687C/en not_active Expired - Lifetime
- 2005-05-13 PL PL10075450T patent/PL2305245T3/pl unknown
- 2005-05-13 SI SI200532054A patent/SI2070530T1/sl unknown
2012
- 2012-04-26 US US13/457,216 patent/US20130274175A1/en not_active Abandoned
- 2012-06-19 JP JP2012138170A patent/JP6101010B2/ja not_active Expired - Lifetime
2016
- 2016-05-13 CY CY20161100404T patent/CY1117501T1/el unknown
2019
- 2019-02-28 CY CY20191100248T patent/CY1121284T1/el unknown

Also Published As

Publication number	Publication date
JP2007537290A (ja)	2007-12-20
PL2305244T3 (pl)	2017-04-28
SI2305245T1 (sl)	2019-04-30
PT2305245T (pt)	2019-03-19
CY1121284T1 (el)	2020-05-29
EP1765312A4 (de)	2007-08-22
US20130274175A1 (en)	2013-10-17
US20070173462A1 (en)	2007-07-26
ES2608046T3 (es)	2017-04-05
TR201902533T4 (tr)	2019-03-21
PT2305244T (pt)	2016-12-29
HUE043945T2 (hu)	2019-09-30
PL2070530T3 (pl)	2016-06-30
DK2305244T3 (en)	2017-01-30
CY1117501T1 (el)	2017-04-26
EP2305245B1 (de)	2019-01-02
EP1765312A2 (de)	2007-03-28
LT2305245T (lt)	2019-03-12
JP6101010B2 (ja)	2017-03-22
EP2070530A1 (de)	2009-06-17
JP2012197309A (ja)	2012-10-18
MX344601B (es)	2016-12-20
CA2566687C (en)	2012-07-24
EP2070530B1 (de)	2016-02-17
ES2565609T3 (es)	2016-04-05
SI2070530T1 (sl)	2016-05-31
DK2305245T3 (en)	2019-03-25
EP2305245A1 (de)	2011-04-06
WO2005112990A3 (en)	2006-01-05
MXPA06013245A (es)	2007-05-09
WO2005112990A2 (en)	2005-12-01
CA2776682A1 (en)	2005-12-01
CA2566687A1 (en)	2005-12-01
HUE031581T2 (en)	2017-07-28
EP2305244B1 (de)	2016-10-12
JP5734545B2 (ja)	2015-06-17
ES2713954T3 (es)	2019-05-24
PL2305245T3 (pl)	2019-05-31
EP1765312B1 (de)	2011-07-13
HUE027757T2 (en)	2016-11-28
EP2305244A1 (de)	2011-04-06
DK2070530T3 (da)	2016-05-17
ES2395404T3 (es)	2013-02-12
BRPI0511119A (pt)	2007-11-27

Legal Events

Date	Code	Title	Description
2012-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
CY1121284T1 (el)	2020-05-29	Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων
BRPI0519384A2 (pt)	2009-01-20	misturas sinergÍsticas com efeito inseticida e fungicida
ATE402180T1 (de)	2008-08-15	Verbindungen zur behandlung von dyslipidemie
MX2019015895A (es)	2020-02-07	Nuevos derivados de azaquinolina.
MX2009000285A (es)	2009-06-08	Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
BRPI0606690A2 (pt)	2009-07-14	composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
GB2480772A (en)	2011-11-30	Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
EA200900802A1 (ru)	2010-04-30	Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru)	2006-08-25	Способы и композиции для лечения амилоидных заболеваний
CY1108196T1 (el)	2014-02-12	Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα
ATE534391T1 (de)	2011-12-15	3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
NO20074251L (no)	2007-09-11	Nye isotiazolokinoloner of relaterte forbindelser som anti-infektive midler
EA200800444A1 (ru)	2008-06-30	8-МЕТОКСИ-9Н-ИЗОТИАЗОЛО[5,4-b]ХИНОЛИН-3,4-ДИОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ПРОТИВОИНФЕКЦИОННЫХ СРЕДСТВ
ATE412414T1 (de)	2008-11-15	3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
EA200600374A1 (ru)	2006-08-25	Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
ATE450146T1 (de)	2009-12-15	Beizmittel-formulierungen enthaltend einen biologisch abbaubaren teilaromatischen polyester
BRPI0615614A2 (pt)	2009-05-19	compostos orgánicos
ATE475408T1 (de)	2010-08-15	Formulierungen von tipifarnib zur intravenösen verabreichung
DE602005007471D1 (de)	2008-07-24	Satraplatin zur behandlung von resistenten oder refrkatären tumoren
ATE457727T1 (de)	2010-03-15	Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
MX2022001722A (es)	2022-03-11	Tecnicas de sobremoldeo y articulos relacionados producidos a partir de las mismas.
BRPI0511908A (pt)	2008-01-15	derivados de aza-biciclo[3.1.0]hex-1-il ativos como antagonistas de nk1
ATE389439T1 (de)	2008-04-15	Behandlung von einschlusskörper-myositis
DE602004028113D1 (de)	2010-08-26	Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung
AR010585A1 (es)	2000-06-28	Compuesto derivado de oxometileno, proceso para su preparacion, composicion farmaceutica que lo contiene y su uso para la fabricacion de agentesterapeuticos